ZyVersa Therapeutics Stock Forward View
| ZVSA Stock | 0.16 0.01 5.59% |
ZyVersa Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast ZyVersa Therapeutics stock prices and determine the direction of ZyVersa Therapeutics's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of ZyVersa Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At this time, the RSI of ZyVersa Therapeutics' share price is approaching 49. This usually means that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling ZyVersa Therapeutics, making its price go up or down. Momentum 49
Impartial
Oversold | Overbought |
Wall Street Target Price 20 |
Using ZyVersa Therapeutics hype-based prediction, you can estimate the value of ZyVersa Therapeutics from the perspective of ZyVersa Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of ZyVersa Therapeutics on the next trading day is expected to be 0.13 with a mean absolute deviation of 0.01 and the sum of the absolute errors of 0.60. ZyVersa Therapeutics after-hype prediction price | USD 0.18 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of ZyVersa Therapeutics to cross-verify your projections. ZyVersa Therapeutics Additional Predictive Modules
Most predictive techniques to examine ZyVersa price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for ZyVersa using various technical indicators. When you analyze ZyVersa charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
ZyVersa Therapeutics Cash Forecast
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the ZyVersa Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2010-12-31 | Previous Quarter 1.8 M | Current Value 2.4 M | Quarterly Volatility 1.6 M |
ZyVersa Therapeutics Naive Prediction Price Forecast For the 31st of January
Given 90 days horizon, the Naive Prediction forecasted value of ZyVersa Therapeutics on the next trading day is expected to be 0.13 with a mean absolute deviation of 0.01, mean absolute percentage error of 0.0003, and the sum of the absolute errors of 0.60.Please note that although there have been many attempts to predict ZyVersa Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that ZyVersa Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
ZyVersa Therapeutics Stock Forecast Pattern
| Backtest ZyVersa Therapeutics | ZyVersa Therapeutics Price Prediction | Buy or Sell Advice |
ZyVersa Therapeutics Forecasted Value
In the context of forecasting ZyVersa Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. ZyVersa Therapeutics' downside and upside margins for the forecasting period are 0 and 11.14, respectively. We have considered ZyVersa Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of ZyVersa Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent ZyVersa Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 109.9581 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0098 |
| MAPE | Mean absolute percentage error | 0.06 |
| SAE | Sum of the absolute errors | 0.5952 |
Predictive Modules for ZyVersa Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ZyVersa Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ZyVersa Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ZyVersa Therapeutics After-Hype Price Density Analysis
As far as predicting the price of ZyVersa Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in ZyVersa Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of ZyVersa Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
ZyVersa Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting ZyVersa Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on ZyVersa Therapeutics' historical news coverage. ZyVersa Therapeutics' after-hype downside and upside margins for the prediction period are 0.01 and 11.22, respectively. We have considered ZyVersa Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
ZyVersa Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of ZyVersa Therapeutics is based on 3 months time horizon.
ZyVersa Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as ZyVersa Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ZyVersa Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with ZyVersa Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.71 | 11.01 | 0.01 | 0.17 | 8 Events / Month | 6 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.16 | 0.18 | 0.00 |
|
ZyVersa Therapeutics Hype Timeline
ZyVersa Therapeutics is at this time traded for 0.16. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.17. ZyVersa is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at 0.71%. %. The volatility of related hype on ZyVersa Therapeutics is about 4587.5%, with the expected price after the next announcement by competition of -0.01. The company has Price to Book (P/B) ratio of 0.21. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. ZyVersa Therapeutics recorded a loss per share of 3.32. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of April 2024. Given the investment horizon of 90 days the next projected press release will be in about 8 days. Check out Historical Fundamental Analysis of ZyVersa Therapeutics to cross-verify your projections.ZyVersa Therapeutics Related Hype Analysis
Having access to credible news sources related to ZyVersa Therapeutics' direct competition is more important than ever and may enhance your ability to predict ZyVersa Therapeutics' future price movements. Getting to know how ZyVersa Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how ZyVersa Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| HEPA | Hepion Pharmaceuticals | (1.33) | 13 per month | 0.00 | (0.44) | 13.95 | (25.00) | 78.13 | |
| CDT | Conduit Pharmaceuticals | 0.01 | 10 per month | 0.00 | (0.22) | 10.06 | (11.97) | 32.20 | |
| ENVB | Enveric Biosciences | 0.21 | 9 per month | 0.00 | (0.04) | 14.08 | (16.57) | 121.83 | |
| XAGE | Longevity Health Holdings | (0.13) | 10 per month | 0.00 | (0.04) | 19.23 | (20.45) | 46.80 | |
| NIVF | NewGenIvf Group Limited | (0.27) | 6 per month | 0.00 | (0.31) | 15.95 | (21.23) | 44.03 | |
| WORX | Scworx Corp | 0.1 | 9 per month | 0.00 | (0.03) | 10.34 | (9.68) | 57.56 | |
| INDP | Indaptus Therapeutics | 0.01 | 6 per month | 0.00 | (0.06) | 13.58 | (12.56) | 51.64 | |
| JSPR | Jasper Therapeutics | (0.56) | 11 per month | 0.00 | (0.1) | 7.73 | (9.04) | 31.75 | |
| ONCO | Onconetix | (0.40) | 5 per month | 0.00 | (0.17) | 9.09 | (12.46) | 36.81 | |
| SLXN | Biomotion Sciences Ordinary | (0.04) | 5 per month | 0.00 | (0.10) | 15.09 | (8.19) | 37.24 |
Other Forecasting Options for ZyVersa Therapeutics
For every potential investor in ZyVersa, whether a beginner or expert, ZyVersa Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. ZyVersa Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in ZyVersa. Basic forecasting techniques help filter out the noise by identifying ZyVersa Therapeutics' price trends.ZyVersa Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ZyVersa Therapeutics stock to make a market-neutral strategy. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
ZyVersa Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how ZyVersa Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ZyVersa Therapeutics shares will generate the highest return on investment. By undertsting and applying ZyVersa Therapeutics stock market strength indicators, traders can identify ZyVersa Therapeutics entry and exit signals to maximize returns.
ZyVersa Therapeutics Risk Indicators
The analysis of ZyVersa Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in ZyVersa Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting zyversa stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.7 | |||
| Semi Deviation | 5.33 | |||
| Standard Deviation | 10.72 | |||
| Variance | 115.02 | |||
| Downside Variance | 89.57 | |||
| Semi Variance | 28.39 | |||
| Expected Short fall | (12.59) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for ZyVersa Therapeutics
The number of cover stories for ZyVersa Therapeutics depends on current market conditions and ZyVersa Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that ZyVersa Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about ZyVersa Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
ZyVersa Therapeutics Short Properties
ZyVersa Therapeutics' future price predictability will typically decrease when ZyVersa Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of ZyVersa Therapeutics often depends not only on the future outlook of the potential ZyVersa Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ZyVersa Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 1.5 M |
Check out Historical Fundamental Analysis of ZyVersa Therapeutics to cross-verify your projections. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. Anticipated expansion of ZyVersa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ZyVersa Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate ZyVersa Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating ZyVersa Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause ZyVersa Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, ZyVersa Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.